-
Data show the critical pathways regulating the expression of ADAMDEC1 and the roles of enhancer RNAs and mechanistically links E1A binding protein p300 (p300) and enhancer RNAs, which is dependent on NF-kappa B (NFkappaB).
-
Studies demonstrate that miR-500a-5p functions as a tumour suppressor in CRC by targeting the p300/YY1/HDAC2 axis, which contributes to the development of and provides new potential candidates for CRC therapy.
-
data explain how cellular signalling and the activation and dimerization of transcription factors control the activation of p300, and therefore explain why gene transcription is associated with chromatin acetylation
-
We conclude that there is now more firm evidence that variants in these specific regions of CREBBP and EP300 result in a phenotype that differs from RSTS, and that this phenotype may be heterogeneous.
-
findings demonstrate that RACK1 is involved in p300/GATA4-dependent hypertrophic responses in cardiomyocytes and is a promising therapeutic target for heart failure
-
As a crucial tumor promoter, p300 promotes cell proliferation, migration, and invasion in non-small cell lung cancer cells
-
Next-generation sequencing revealed specific mutations in EP300 to be associated with the mutational patterns in typical breast cancer genes and long-term outcome of triple-negative breast cancer patients.
-
While the primary tumours showed mutations in genes associated with cell adhesion and motility, brain metastases acquired mutations in adaptive, cytoprotective genes involved in response to cellular stress such as Keap-1, Nrf2 and P300, which are key players of the Keap1-Nrf2-ARE survival pathway.
-
Systems approach revealed that histone deacetylation is strongly associated with the suppression of EP300 target genes implicated in diabetes.
-
novel EP300 mutations were found in Rubinstein-Taybi 2 syndrome
-
p300 autoacetylation is associated with tongue neoplasms.
-
CREBBP and p300 may contribute to genome stability by fine-tuning the functions of DNA damage signaling and DNA repair factors, thereby expanding their role as tumor suppressors. (Review)
-
Results show that p300 recruitment along with binding to histones are required for cMyb to fully activate transcription of a chromatinembedded gene.
-
Our data show that the hyperacetylation of Tau by p300 histone acetyltransferase (HAT) disfavors liquid-liquid phase separation , inhibits heparin-induced aggregation, and impedes access to LLPS-initiated microtubule assembly
-
EP300 variants are associated with Rubinstein-Taybi syndrome.
-
High P300 expression is associated with recurrence in prostate cancer.
-
Data generated with primary human hepatic stellate cells (HSC) supports that stiffness-mediated HSC activation requires p300.
-
The histone acylation activity of p300 can be activated by pre-existing lysine crotonylation through a positive feedback mechanism.
-
epigenomic profiling of clear cell renal cell carcinoma (ccRCC) establishes a compendium of somatically altered cis-regulatory elements, uncovering new potential targets including ZNF395. Loss of VHL, a ccRCC signature event, causes pervasive enhancer malfunction, with binding of enhancer-centric HIF2a and recruitment of histone acetyltransferase p300 at preexisting lineage-specific promoter-enhancer complexes
-
Histone acetyltransferase EP300 is necessary for the transcription factor SOX2 activity in basal cells, including for induction of the squamous fate. EP300 copy number gains are common in squamous cell carcinoma SQCCs, including lung cancer SQCC cell lines.
